Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology announced that Phil Pang, M.D., Ph.D., their executive vice president and chief medical officer, will present at the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on October 18, 2022, at 10:30 a.m. PT / 1:30 p.m. ET. A live webcast of the presentation can be accessed on the Vir website and will be available for 30 days.
Vir focuses on immunology and has a pipeline targeting serious infectious diseases such as COVID-19 and hepatitis B.
Vir Biotechnology announces a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), initially valued at $55 million, to develop VIR-2482, a monoclonal antibody for influenza. The contract has the potential to extend up to $1 billion for influenza and other infectious disease candidates. The Phase 2 trial for VIR-2482 is anticipated to start in late 2022, with initial data expected by mid-2023. This collaboration is aimed at enhancing public health responses to infectious disease threats.
On September 22, 2022, Vir Biotechnology announced the dosing of the first patient in the Phase 2 SOLSTICE trial aimed at treating chronic hepatitis D virus (HDV) infection. This trial evaluates the efficacy of VIR-2218 and VIR-3434, a combination strategy designed to reduce HDV viremia and block viral entry. Approximately 12 million people worldwide are affected by HDV, underscoring the urgency for effective treatment options. The initial results from SOLSTICE are expected in 2023, marking a significant step forward in addressing this serious health challenge.
Vir Biotechnology will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:05 p.m. ET. Investors can access a live webcast via the Vir website, which will be archived for 30 days. The company focuses on treating serious infectious diseases using advanced immunologic technologies, with a pipeline aimed at COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology reported a net loss of $76.5 million for Q2 2022, significantly down from a net income of $61.8 million in Q2 2021. Total revenues dropped to $40.6 million, influenced by a $397.4 million non-cash charge related to excess sotrovimab supply. Despite this, the company holds over $2.6 billion in cash and equivalents, expected to fund operations for up to five years. Notably, approximately 265,000 sotrovimab doses were delivered in Q2 2022, exceeding initial projections, and the company anticipates important clinical milestones in its COVID-19 and hepatitis programs.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced it will release a corporate update and financial results for Q2 2022 on August 4, 2022, after market close. Investors can access the press release on the company's website. Vir focuses on developing treatments for serious infectious diseases using innovative immunological technologies. Its pipeline includes candidates targeting COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology (Nasdaq: VIR) announced the resignation of Herbert “Skip” Virgin, M.D., Ph.D., effective August 31, 2022. He has accepted a position as chief medical officer at Altos Institute of Medicine but will remain on Vir’s Scientific Advisory Board. Phil Pang, M.D., Ph.D., Vir’s current chief medical officer, will oversee research and development during the transition. Virgin's contributions over nearly five years were pivotal in launching Vir's first product and advancing its pipeline against infectious diseases.
Vir Biotechnology announced promising results from its ongoing HBV clinical trials, presenting data on VIR-2218 and VIR-3434 at the International Liver Congress 2022. The six-dose regimen of VIR-2218 showed greater and lasting reductions in hepatitis B surface antigen (HBsAg). VIR-3434 demonstrated rapid reductions in HBsAg with the highest efficacy at the 300 mg dose. The company plans to start Part B of the Phase 2 MARCH trial by June's end. There were no safety concerns reported, and further data readouts are anticipated in 2022 and 2023.
Vir Biotechnology (Nasdaq: VIR) announced three accepted abstracts for oral and poster presentations at the International Liver Congress 2022, taking place June 22-26. The oral presentation will focus on Phase 2 trial data for VIR-2218, a potential functional cure for chronic hepatitis B virus (HBV) infection. Additionally, one poster will discuss dose-dependent durability from a Phase 1 trial of VIR-3434, while another will present preclinical data on the combination therapy of VIR-2218 and VIR-3434. These developments highlight the company's commitment to addressing the global health challenge posed by HBV.
Vir Biotechnology (Nasdaq: VIR) will host its 2022 Annual General Meeting (AGM) on May 20, 2022, at 11:30 a.m. PT, in a virtual format. Stockholders of record as of March 28, 2022, can participate by accessing the meeting via a provided online link. The virtual access will open at 11:15 a.m. PT. Investors are encouraged to vote and submit proxies ahead of the meeting, utilizing instructions from the proxy materials. Vir focuses on immunologic treatments for infectious diseases, including COVID-19 and hepatitis.
FAQ
What is the current stock price of Vir Biotechnology (VIR)?
What is the market cap of Vir Biotechnology (VIR)?
